Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that FGFR2::v status confers therapeutic sensitivity to Elacestrant in patients with Cholangiocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pemigatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2025-08-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |